Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
for High-Risk Non-Muscle-Invasive Bladder Cancer
65 locations incl. Phoenix
Sponsor: CG Oncology, Inc.
Sex: All·Age: 18+
Code: NCT06567743·Phase 2·Recruiting